SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.28
+0.17 (+0.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close42.11
Open42.01
Bid38.25 x 800
Ask42.70 x 1100
Day's Range41.97 - 42.67
52 Week Range37.67 - 45.62
Volume1,194,253
Avg. Volume1,093,861
Market Cap106.298B
Beta (3Y Monthly)0.38
PE Ratio (TTM)21.79
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.74 (3.98%)
Ex-Dividend Date2019-05-07
1y Target Est52.00
  • Alphabet to Aid Pharma Giants Enhance Clinical Trial Process
    Zacks3 days ago

    Alphabet to Aid Pharma Giants Enhance Clinical Trial Process

    Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.

  • Lilly (LLY) Launches Half-Priced Version of Humalog Insulin
    Zacks3 days ago

    Lilly (LLY) Launches Half-Priced Version of Humalog Insulin

    Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

  • Is Sanofi (EPA:SAN) Trading At A 32% Discount?
    Simply Wall St.5 days ago

    Is Sanofi (EPA:SAN) Trading At A 32% Discount?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Sanofi (EPA:SAN) as...

  • Pfizer's Eczema Candidate Meets All Goals in Phase III Study
    Zacks10 days ago

    Pfizer's Eczema Candidate Meets All Goals in Phase III Study

    Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

  • PR Newswire11 days ago

    Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019

    - Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma - Longer-term Libtayo® ...

  • Sanofi Joins Drugmakers' Bid to Treat Patients With Software
    Bloomberg11 days ago

    Sanofi Joins Drugmakers' Bid to Treat Patients With Software

    Working with partner Happify Health, the French drugmaker is studying a potential digital therapy for patients with depression and multiple sclerosis. “The regulatory pathway has really become much more amenable, and we know for certain diseases, a digital therapeutic can actually be very effective,” Chief Digital Officer Ameet Nathwani said in an interview at Sanofi’s headquarters in Paris. Drugmakers are looking increasingly at apps and other software tools that are proven in trials, reviewed by regulators and prescribed by doctors to treat a range of diseases.

  • Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
    Zacks16 days ago

    Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

    Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

  • Sanofi Recognized by DiversityInc as a Top 50 Company
    PR Newswire18 days ago

    Sanofi Recognized by DiversityInc as a Top 50 Company

    BRIDGEWATER, N.J., May 8, 2019 /PRNewswire/ -- For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes the nation's top companies for diversity and inclusion management. Sanofi has also been named to two of DiversityInc's Specialty Lists – Top Companies for LGBT Employees and Top Companies for Philanthropy.

  • Here's the Bad News That Derailed Regeneron's Stock
    Motley Fool18 days ago

    Here's the Bad News That Derailed Regeneron's Stock

    This big-cap biotech has a problem or two on its hands.

  • PR Newswire18 days ago

    Sanofi Announces Licensing of Dupixent® ▼ (dupilumab) in the EU for the Treatment of Severe Asthma With Type 2 Inflammation

    GUILDFORD, England , May 8, 2019 /PRNewswire/ -- FOR UK MEDIA ONLY  The first biologic licensed in the EU for severe asthma with type 2 inflammation, as characterised by raised blood eosinophils and/or ...

  • Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss
    InvestorPlace19 days ago

    Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss

    Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday.Source: Shutterstock Regeneron Pharmaceuticals (NASDAQ:REGN) reported earnings per share of $4.45 for the first quarter of the year. This is a drop from the company's earnings per share of $4.67 from the first quarter of 2018. It was also a major blow to REGN stock by coming in short of Wall Street's earnings per share estimate of $5.46 for the period.The Regeneron Pharmaceuticals earnings report for the first quarter of 2019 also includes net income of $461 million. That's down from the company's net income of $478 million reported in the same period of the year prior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOperating income reported by Regeneron Pharmaceuticals in its earnings report for the first quarter of the year comes in at $480 million. This is a decrease from the company's operating income of $567 million reported in the first quarter of the previous year.Regeneron Pharmaceuticals earnings for the first quarter of 2019 has revenue coming in at $1.71 billion. This is better than the company's revenue of $1.51 billion reported during the same time last year. However, it was bad news for REGN stock by missing analysts' revenue estimate of $1.76 billion for the quarter. * 7 Strong Buy Stocks That Tick All the Boxes Regeneron Pharmaceuticals notes that it is now expecting lower reimbursement from Sanofi (NASDAQ:SNY) for 2019. This has it expecting reimbursement between $500 million and $535 million. It was previously expecting this to be in the range of $510 million to $560 million.REGN stock was down 5% as of Tuesday morning. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss appeared first on InvestorPlace.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily19 days ago

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why
    Investor's Business Daily20 days ago

    A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why

    Esperion popped Monday after the Food and Drug Administration accepted its applications for a pair of cholesterol treatments called bempedoic acid and bempedoic acid plus ezetimibe.

  • The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
    Zacks20 days ago

    The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

    The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

  • Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
    Zacks23 days ago

    Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

    Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

  • Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV  Drugs Get EU Nod
    Zacks23 days ago

    Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

    Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

  • Benzinga24 days ago

    5 Biotech Stocks With Near-Term Catalysts Ahead

    The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.

  • A Look at Sanofi’s Diabetes Franchise in the First Quarter
    Market Realist24 days ago

    A Look at Sanofi’s Diabetes Franchise in the First Quarter

    Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Diabetes franchise revenuesIn the first quarter, Sanofi’s (SNY) Diabetes franchise reported net sales of 1.29 billion euros, a YoY decline of 6.9% on a CER

  • Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
    Zacks24 days ago

    Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

    Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

  • Sanofi’s Immunology Portfolio in the First Quarter
    Market Realist24 days ago

    Sanofi’s Immunology Portfolio in the First Quarter

    Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Immunology revenuesIn the first quarter, Sanofi’s (SNY) Immunology franchise reported net sales of 359 million euros, a YoY rise of 186.3% on a CER (constant

  • Benzinga24 days ago

    The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...

  • How Sanofi’s Rare Blood Disorder Portfolio Performed in Q1
    Market Realist24 days ago

    How Sanofi’s Rare Blood Disorder Portfolio Performed in Q1

    Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Rare blood disorder revenues In the first quarter, Sanofi’s Rare Blood Disorder franchise reported net sales of 274 million euros, a YoY rise of 296.9% on a CER

  • PR Newswire25 days ago

    FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

    BRIDGEWATER, N.J., May 1, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection. Dengvaxia is the first and only vaccine approved for protection against dengue in endemic areas of the U.S. "Dengue is endemic and prone to outbreaks in several U.S. territories, including Puerto Rico, the U.S. Virgin Islands and American Samoa.

  • Analyzing Sanofi’s Oncology Portfolio in the First Quarter
    Market Realist25 days ago

    Analyzing Sanofi’s Oncology Portfolio in the First Quarter

    Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Oncology revenuesIn the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange